ArticleCNS neuroscience & therapeutics2025
Alpinetin Targets Mitophagy Pathways to Mitigate Parkinson's Disease Progression.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Genetic architecture and molecular pathogenesis of Parkinson's disease: emerging mechanisms and therapeutic targets.Metabolic brain disease · 2026Review
- Brain Alterations Linked to the MPTP Mouse Model of Parkinson's Disease Uncovered by Diffusion Kurtosis Imaging and Magnetic Resonance Spectroscopy.CNS neuroscience & therapeutics · 2026Article
- Decoding Adipose Tissue Phenotypic Switching: From Mechanisms to Computational Drug Discovery.Current obesity reports · 2026Review
- Alpinetin Targets Mitophagy Pathways to Mitigate Parkinson's Disease Progression.CNS neuroscience & therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsParkinson's disease (PD) is a complex neurodegenerative disorder lacking disease-modifying therapies. This study aimed to systematically investigate the therapeutic potential and underlying mechanisms of Alpinetin in PD.
methodsAn integrated approach combining network pharmacology and molecular docking was employed to predict the core targets and pathways of Alpinetin in PD. These computational predictions were subsequently validated through in vivo animal experiments.
resultsNetwork pharmacology analysis predicted that Alpinetin exerts its effects by modulating mitophagy and dopaminergic synaptic pathways. Molecular docking revealed strong binding affinities between Alpinetin and key targets, including HIF1A, SQSTM1, and SRC. Guided by these findings, animal experiments confirmed the neuroprotective effects of Alpinetin, aligning with the predicted mechanisms.
conclusionOur findings demonstrate that Alpinetin has significant therapeutic potential for PD, likely mediated through the regulation of mitophagy and dopaminergic synapses. This study elucidates the molecular targets and mechanisms of Alpinetin, providing a solid foundation for its further investigation as an anti-PD agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.